Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled, Ascending Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of MGTA-145 in Healthy Subjects Administered as a Single Agent, as Well as in Combination With Plerixafor

Next Previous
Trial Profile

A Randomized, Placebo-Controlled, Ascending Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of MGTA-145 in Healthy Subjects Administered as a Single Agent, as Well as in Combination With Plerixafor

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EN 145 (Primary) ; Plerixafor (Primary)
  • Indications Stem cell mobilisation
  • Focus Adverse reactions; Proof of concept
  • Sponsors Magenta Therapeutics

Most Recent Events

  • 15 Mar 2021 According to a Magenta Therapeutics media release, data presented at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting.
  • 03 Mar 2021 According to a Magenta Therapeutics media release, data from this study were presented at the Transplantation and Cellular Therapy (TCT) Annual Meeting (2021).
  • 11 Jan 2021 According to a Magenta Therapeutics media release, data from this trial will be presented at the upcoming presentations at the 2021 Transplantation and Cellular Therapy (TCT) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top